Meisner Lara
SEC CIK 1883986 · EDGAR
BoughtSold
Most active insiders at BCAX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | $4.80M | — |
| 2 | Cohlhepp Ryan | Pres, COO, Interim CEO, Dir | — | $4.60M |
| 3 | Mazumdar Claire | CEO, Dir | — | $4.06M |
| 4 | Hyep Ivan | CFO | — | $3.24M |
| 5 | Raben David | Chief Medical Off | — | $1.15M |
| 6 | Meisner Lara | CLO | — | $498.7K |
Transactions 23
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-01 | 2025-09-29 | BCAX | Bicara Therapeutics Inc. | Meisner Lara | CLO | M - OptEx | $9.24 | +33.8K | 33.8K | New | +$312.4K |
| D | 2025-10-01 | 2025-09-29 | BCAX | Bicara Therapeutics Inc. | Meisner Lara | CLO | S - Sale+OE | $14.75 | -33.8K | 0 | -100% | -$498.7K |
| D | 2025-09-17 | 2025-09-15 | BCAX | Bicara Therapeutics Inc. | Meisner Lara | CLO | S - Sale+OE | $11.49 | -15.8K | 0 | -100% | -$181.9K |
| D | 2025-09-17 | 2025-09-15 | BCAX | Bicara Therapeutics Inc. | Meisner Lara | CLO | M - OptEx | $5.45 | +15.8K | 15.8K | New | +$86.3K |
| D | 2025-06-18 | 2025-06-16 | BCAX | Bicara Therapeutics Inc. | Meisner Lara | CLO | S - Sale+OE | $10.43 | -15.8K | 0 | -100% | -$165.1K |
| D | 2025-06-18 | 2025-06-16 | BCAX | Bicara Therapeutics Inc. | Meisner Lara | CLO | M - OptEx | $5.45 | +15.8K | 15.8K | New | +$86.3K |
| DMT | 2025-03-18 | 2025-03-14 | BCAX | Bicara Therapeutics Inc. | Meisner Lara | CLO | S - Sale+OE | $12.90 | -79.1K | 30.6K | -72% | -$1.02M |
| DT | 2025-03-18 | 2025-03-14 | BCAX | Bicara Therapeutics Inc. | Meisner Lara | CLO | M - OptEx | $5.45 | +79.1K | 79.1K | New | +$431.3K |
| DM | 2023-06-20 | 2023-06-15+ | VRDN | Viridian Therapeutics, Inc.\DE | Meisner Lara | CLO | S - Sale+OE | $28.02 | -2,296 | 30.0K | -7% | -$64.3K |
| DM | 2023-06-20 | 2023-06-15+ | VRDN | Viridian Therapeutics, Inc.\DE | Meisner Lara | CLO | M - OptEx | $23.03 | +2,296 | 30.0K | +8% | +$52.9K |
| DM | 2023-06-06 | 2023-06-02+ | VRDN | Viridian Therapeutics, Inc.\DE | Meisner Lara | CLO | M - OptEx | $17.38 | +7,500 | 30.5K | +33% | +$130.4K |
| DM | 2023-06-06 | 2023-06-02+ | VRDN | Viridian Therapeutics, Inc.\DE | Meisner Lara | CLO | S - Sale+OE | $24.82 | -7,500 | 30.0K | -20% | -$186.1K |
| 2023-03-10 | 2023-03-09 | VRDN | Viridian Therapeutics, Inc.\DE | Meisner Lara | GC, Sec | S - Sale | $29.07 | -30.0K | 0 | -100% | -$871.3K | |
| DM | 2023-01-25 | 2023-01-23 | VRDN | Viridian Therapeutics, Inc.\DE | Meisner Lara | GC, Sec | M - OptEx | $20.56 | +6,843 | 6,843 | New | +$140.7K |
| D | 2023-01-25 | 2023-01-23 | VRDN | Viridian Therapeutics, Inc.\DE | Meisner Lara | GC, Sec | S - Sale+OE | $35.66 | -6,843 | 0 | -100% | -$244.0K |
| DM | 2022-12-22 | 2022-12-20+ | VRDN | Viridian Therapeutics, Inc.\DE | Meisner Lara | GC, Sec | M - OptEx | $23.03 | +16.9K | 16.3K | New | +$389.8K |
| DM | 2022-12-22 | 2022-12-20+ | VRDN | Viridian Therapeutics, Inc.\DE | Meisner Lara | GC, Sec | S - Sale+OE | $29.15 | -16.9K | 0 | -100% | -$493.4K |
| DM | 2022-12-19 | 2022-12-15+ | VRDN | Viridian Therapeutics, Inc.\DE | Meisner Lara | GC, Sec | M - OptEx | $23.03 | +1,597 | 1,297 | New | +$36.8K |
| DM | 2022-12-19 | 2022-12-15+ | VRDN | Viridian Therapeutics, Inc.\DE | Meisner Lara | GC, Sec | S - Sale+OE | $28.37 | -1,597 | 0 | -100% | -$45.3K |
| DM | 2022-12-14 | 2022-12-12+ | VRDN | Viridian Therapeutics, Inc.\DE | Meisner Lara | GC, Sec | M - OptEx | $23.03 | +16.3K | 600 | New | +$374.4K |
| DM | 2022-12-14 | 2022-12-12+ | VRDN | Viridian Therapeutics, Inc.\DE | Meisner Lara | GC, Sec | S - Sale+OE | $28.12 | -16.3K | 0 | -100% | -$457.1K |
| D | 2022-11-16 | 2022-11-15 | VRDN | Viridian Therapeutics, Inc.\DE | Meisner Lara | GC, Sec | S - Sale+OE | $22.05 | -8,125 | 0 | -100% | -$179.2K |
| D | 2022-11-16 | 2022-11-15 | VRDN | Viridian Therapeutics, Inc.\DE | Meisner Lara | GC, Sec | M - OptEx | $14.00 | +8,125 | 8,125 | New | +$113.8K |
Purchase Sale Sale after option exercise All abbreviations